The suit has been filed in the U.S. District Court for the District of Columbia against Cephalon. According to the Commission, Cephalon, faced with threat to its Provigil monopoly, paid more than $200 million to generic drug companies to abandon their patent challenges and forgo entry into the market until April 2012. As Cephalon's CEO allegedly put it shortly after entering these settlements: "We were able to get six more years of patent protection. That's $4 billion in sales no one expected".
The FTC is clearly taking the issue very seriously, see also here.
-
ArsTechnica, here .
-
Coalition for App Fairness, here.
-
.png)
EC, here . [NotebookLM's own DeepDive here , just for fun] In our Article 19 Report we discussed this and how it could eventually trans... -
T. Davies, here .
-
The NerdReich, here . [To be clear: not the name of a demanding ski slope up in Trento's mountains]. -
Just for a laugh: Anti-American Antitrust: How Foreign Governments Target U.S. Businesses | House Judiciary Committee Republicans . Portu...
-
BertHub.eu, here .
-
D. Dayen, here .
-
M. Markovitz, here . Final Report, here .
No comments:
Post a Comment